Bicara Therapeutics has priced an underwritten public offering totaling $150 million, comprising 7.175 million shares of common stock at $16.00 per share and 2.2 million pre-funded warrants. The offering is expected to close on February 26, 2026, subject to customary closing conditions and regulatory approvals.
The biopharmaceutical company intends to allocate the capital toward multiple strategic initiatives, including advancement of its lead therapeutic candidate ficerafusp alfa and acceleration of development programs in head and neck cancer indications. Additional proceeds will support the establishment of commercial infrastructure and manufacturing expansion efforts to support future product launches.
The offering was underwritten by major financial institutions, demonstrating investor confidence in the company's pipeline and commercial strategy. This capital raise strengthens Bicara's financial position to execute its clinical and commercial objectives through anticipated key value-creation milestones.